FDA Seeks Public Input to Advance Ibogaine Research for Addiction Treatment

The U.S. Food and Drug Administration (FDA) is seeking public input to support research into ibogaine, a psychedelic drug, as a potential treatment for opioid and alcohol use disorders. This initiative follows a presidential executive order to accelerate research into psychedelic medicine. The FDA has already allowed an early-phase clinical study of noribogaine hydrochloride, an ibogaine derivative, for alcohol use disorder.